EBITDA

A hedge fund's subtle move in Unite Group offers a rare glimpse into the high-stakes strategy behind the UK's student housing consolidation boom.

A new report reveals a shocking gap: as autonomous AI agents flood enterprises, only 21% have visibility, creating a massive, unaddressed security risk.

After key legal setbacks, Pason Systems settles its IP litigation. We decode what this confidential agreement means for investors and future innovation.

Sana Biotech’s new data shows it can edit stem cells directly in the body, a potential game-changer for blood disorders and a challenge to current therapies.

PHOTRON's takeover of AOS Technologies signals a major shift in the high-speed camera market, with deep implications for automotive safety and defense.

After explosive growth under private equity, hunting apparel giant KUIU is sold to a new conservation-minded ownership group. What's next for the brand?

A new awards program from a proven name in indie recognition is celebrating the unsung heroes of small business, from therapy to pet spas.

A new investment narrative targets 'essential' sectors. A deep dive reveals a complex mix of real strategy, verifiable progress, and pure promotion.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

SS Innovations is betting its cost-efficient SSi Mantra robot can break into the U.S. market. Will affordability democratize the operating room?

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

A new partnership aims to revolutionize public safety with faster, smarter security screening. But can advanced AI balance security with personal privacy?

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

A new wave of affordable, user-friendly robots is here. A new mower ditches complexity, but what are the strategic trade-offs for consumers and the market?

Toshiba partners with a 38-year local veteran in Trinidad & Tobago. We analyze the strategy behind a deal that's more than just printers—it's a play for an entire region.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

A deepening corporate governance battle pits STAAR Surgical's board against its largest shareholder and all major proxy firms over a $1.5B Alcon deal.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

Onex cashes out of Ryan Specialty with a stunning 49% IRR. We dive into the strategy behind the $1.2B exit and what it signals for specialty insurance.